PF-05230905

PF-05230905 is a bivalent anti-tumor necrosis factor alpha (TNF-alpha) Nanobody construct developed for the treatment of inflammatory diseases such as rheumatoid arthritis. It utilizes pegylation technology to extend its half-life and is administered via subcutaneous or intravenous injection. The drug was initially developed by Ablynx (now a subsidiary of Sanofi), with Pfizer previously involved in its development through an acquisition of Wyeth. Its mechanism of action involves antagonism of TNF-alpha, a key cytokine in inflammation and immune regulation. Clinical development reached Phase 1 trials in healthy volunteers and Phase 2 readiness for rheumatoid arthritis before rights were returned to Ablynx/Sanofi[1][2][3][4][5][7].